Shingrix Dosage/Direction for Use

Posology: The primary vaccination schedule consists of two doses of 0.5 mL each: an initial dose followed by a second dose 2 months later.
If flexibility in the vaccination schedule is necessary, the second dose can be administered between 2 and 6 months after the first dose (see Pharmacology: Pharmacodynamics under Actions).
For subjects who are or might become immunodeficient or immunosuppressed due to disease or therapy, and whom would benefit from a shorter vaccination schedule, the second dose can be given 1 to 2 months after the initial dose (see Pharmacology: Pharmacodynamics under Actions).
The need for booster doses following the primary vaccination schedule has not been established (see Pharmacology: Pharmacodynamics under Actions).
Shingrix can be given with the same schedule in individuals previously vaccinated with live attenuated HZ vaccine (see Pharmacology: Pharmacodynamics under Actions).
Shingrix is not indicated for prevention of primary varicella infection (chickenpox).
Paediatric population: The safety and efficacy of Shingrix in children and adolescents have not been established.
No data are available.
Method of administration: For intramuscular injection only, preferably in the deltoid muscle.
For instructions on reconstitution of the medicinal product before administration, see Use and Handling under Cautions for Usage.